ࡱ> prmnoq` nbjbjqPqP <::e?    jvXvXvX8X4Y.%uhZ6[4,\,\,\]_9`P1Ү$ݸhE Jbc]"]JbJb ,\,\7/(j(j(jJb8 R,\ ,\(jJb(j(jS " ǫ,\Z OvXg#4۬E0uWp"hhǫ ǫ`Z`@(j#a4Wa```j"```uJbJbJbJb.%.%.%12VD.%.%.%2V& |f + FEMALE GENITALIA I VULVA , VAGINA and CERVIX UTERI Student-Learning Objectives: At the end of this lecture the student should be able to: Classify the main diseases affecting vulva, vagina and cervix. Define vulvar and cervical intraepithelial neoplasia. Discuss vulvar and cervical intraepithelial neoplasia in terms of aetiology, epidemiology, pathological features and implications. Describe the clinico-pathological features of invasive squamous cell carcinoma of the vulva. Describe the clinico-pathological features of invasive cervical carcinoma (including the staging of the disease) PRIVATE  VULVA Vulval diseases may be discussed under the following headings: Cysts Infectious/Inflammatory conditions Non-neoplastic epithelial disorders (Chronic vulvar dystrophies) Neoplasms Cysts Most vulval cysts are of little pathological significance. They may be of epidermal or dermal origin. Some are developmental and others are acquired. Cysts and/or abscesses of the Bartholins glands are the most common clinically important cystic lesions of the vulva. Bartholins cysts form secondary to duct obstruction often due to chronic inflammation and scarring. The abscess is often a sequel of gonorrheal infection.  HYPERLINK "http://www.brooksidepress.org/Products/Military_OBGYN/Textbook/Vulva/Bartholin.htm" Clinical picture of Bartholins cyst Infectious/Inflammatory conditions Some of these are sexually transmitted infections (STIs), and include granuloma inguinale, lymphogranuloma venereum, syphilis, herpes simplex and human papillomavirus infection. Non-STIs include Crohn's disease and miscellaneous bacterial and fungal infections. Granuloma Inguinale (GI) This is caused by a gram-negative coccobacillus (Calymmatobacterium granulomatis) and is represented by lesions, which vary from painless papules to ulcerating, necrotic, granulating lesions. The inflammatory infiltrate is rich in macrophages and plasma cells. On special staining with Giemsa or silver stains, the organisms - Donovan bodies - may be seen extracellularly and within macrophages. Lymphogranuloma Venereum (LGV) This is caused by Chlamydia trachomatis and is characterized by inguinal lymph node inflammation and enlargement (buboes). The disease has three phases giving the following lesions: a) Small ulcers (usually painless) - located at the site of the venereal contact b) Bartholin gland inflammation +/- abscess formation c) Scarring with fistulae/strictures of urethra, vagina and/or rectum (in chronic cases). Scarring may lead to lymphatic obstruction with chronic lymphedema, which can cause elephantiasis of the vulva. The histological picture is nonspecific and the organisms are not seen histologically.  HYPERLINK "http://www.brooksidepress.org/Products/OBGYN_101/MyDocuments4/Text/Vulva/LGV1640.jpg" Clincal picture of LGV1  HYPERLINK "http://www.brooksidepress.org/Products/OBGYN_101/MyDocuments4/Text/Vulva/LGV.jpg" Clinical picture of LGV2 Syphilis Primary - characterized by the chancre, a painless papule that usually ulcerates.  HYPERLINK "http://www.brooksidepress.org/Products/OBGYN_101/MyDocuments4/Text/Vulva/1syph.jpg" Chancre Secondary - features include a maculo-papular rash and condylomata lata. The latter are plaque-like lesions represented by epithelial proliferation and a plasma cell rich mononuclear inflammatory infiltrate. The causative organism, Treponema pallidum, may be seen in the lesions when stained with the appropriate silver stain.  HYPERLINK "http://www.brooksidepress.org/Products/OBGYN_101/MyDocuments4/Text/Vulva/2syphb.jpg" Secondary syphilis, condylomata lata Tertiary syphilis rarely affects the vulva. Herpes Simplex Virus (HSV) Infection This is caused by herpes simplex virus (usually type 2) that results in the formation of painful vesicles. There is secondary ulceration with infection. Histological examination shows typical cytopathic effects of the virus that include nuclear homogenization (ground glass appearance) and multinucleation with intranuclear inclusion bodies.  HYPERLINK "http://www.brooksidepress.org/Products/OBGYN_101/MyDocuments4/Text/Vulva/HerpesVulvitis640.jpg" Herpes vulvitis Human papillomavirus (HPV) Infection The importance of this infection lies primarily in the association between HPVs and neoplasia of the vulva and cervix uteri discussed later. Neoplasms Benign These comprise a miscellaneous group and include benign skin adnexal tumours, haemangiomas, lipomas etc. Condylomata acuminata (singular - condyloma acuminatum) are anogenital warts benign sexually transmitted neoplasms (papillomas) caused by HPV. They may occur singly but are usually multiple, and are verrucous, papillomatous lesions comprising stratified squamous epithelium on vascular connective tissue stalks. The squamous epithelium shows the typical cytopathic features of HPV infection koilocytosis and bi- or multinucleation. The koilocyte (from the Greek koilos for hollow) is the classic cytopathic manifestation of HPV infection in squamous epithelium, and is a squamous cell with a prominent perinuclear cytoplasmic halo and a hyperchromatic, raisin-like nucleus. The types of HPV associated with condyloma acuminatum are the low-risk types 6 and 11. They are treated by local ablation surgical removal, cryosurgery, electro-coagulation etc.  HYPERLINK "http://www.phac-aspc.gc.ca/slm-maa/slides/hpv/pages/16.html" Gross photo of condylomata acuminata  HYPERLINK "http://www.visualsunlimited.com/browse/vu364/vu36461.html" Gross photo of condylomata acuminata 2 Malignant These comprise squamous cell carcinoma, malignant melanoma, and basal cell carcinoma. In rare instances, urethral carcinomas may extend to involve the vulva. Adenocarcinomas may arise from skin adnexal structures or Bartholin's gland. Squamous cell carcinoma This may be in situ or invasive. The frequency of progression of in situ disease to invasive is uncertain but has been estimated as 2% to 10%. The term vulvar intraepithelial neoplasia (VIN) has now largely replaced other designations for in situ squamous proliferations of the vulva: VIN I (mild dysplasia) is diagnosed when the lower one-third of the epidermis is replaced by the malignant squamous cells. VIN II (moderate dysplasia) comprises malignant cells in the lower two-thirds of the epidermis. VIN III (severe dysplasia/carcinoma in situ) comprises malignant cells in greater than two-thirds (to the full thickness) of the epidermis.  HYPERLINK "http://www.brooksidepress.org/Products/Military_OBGYN/Textbook/Vulva/vin3.jpg" Gross picture, VIN III Features of HPV infection may be superimposed on VIN, particularly in younger women. Up to about 30 years ago, VIN was usually found in women in the 5th and 6th decades, but currently, about a half of the patients are less than 40 years old. This is thought to be due to the increasing association with HPV infection. Invasive squamous cell carcinoma accounts for greater than 90% of all vulvar malignancies. Over 90% of the patients are post-menopausal and most are over the age of 60. The lesion usually begins on the labia majora, is slow growing and tends to grow in a destructive, infiltrating manner often with ulceration. Inguinal (groin) lymph nodes are the commonest site for metastases.  HYPERLINK "http://www.brooksidepress.org/Products/Military_OBGYN/Textbook/Vulva/vulvaca.jpg" Gross picture of squamous cell ca of vulva;  HYPERLINK "http://www.brooksidepress.org/Products/Military_OBGYN/Textbook/Vulva/SqCaVulva.jpg" Histology of invasive squamous cell ca of vulva The lesions may be multifocal and may be associated with malignancies elsewhere in the genital tract, especially the cervix. There is a strong association with HPV infection and VIN changes may often be seen adjacent to the frank carcinoma. Treatment is usually surgical +/- radiotherapy, and prognosis is related to the presence or absence of lymph node involvement; 5-year survival is 70-80% with negative nodes and 40-50% with positive nodes. Mortality increases with the number of lymph nodes involved by tumour, bilateral involvement of groin nodes and metastases to pelvic lymph nodes. Metastases to the vulva do occur, and are usually seen in advanced carcinoma of the genital tract, most commonly of the cervix. Paget's disease of the vulva usually presents as a scaly, erythematous lesion on the vulva and in most cases represents a metastatic, intra-epidermal adenocarcinoma arising from an underlying sweat gland carcinoma. VAGINA Pathologically, important benign vaginal lesions are uncommon. Perhaps the only one worth mentioning (though uncommon) is vaginal adenosis - metaplastic foci of endocervical glandular-type epithelium in the normal squamous epithelium sometimes related to in utero exposure to diethylstilbestrol (DES). The natural history is that of slow self-healing, but there is said to be an increased (albeit low) risk of clear cell adenocarcinoma in these patients. Malignancies of the vagina include squamous cell carcinoma, adenocarcinoma, rhabdomyosarcoma (sarcoma botryoides), malignant melanoma and metastatic carcinoma. Squamous cell carcinoma comprises over 90% of vaginal malignancies. Most represent extension from cervical cancers and true primary vaginal squamous cell carcinomas are rare. Adenocarcinomas are most commonly found in older patients. Rhabdomyosarcoma (sarcoma botryoides) is a rare malignancy of infants and children, and most occur under 2 years of age. The lesion presents as polypoid masses resembling bunches of grapes (hence the name). The prognosis used to be uniformly poor but has improved considerably with the use of a combination of surgery and multi-agent chemotherapy. Metastatic carcinoma originates from genital and pelvic organs such as cervix, ovary, endometrium, rectum and kidney. CERVIX UTERI PRIVATE  The main diseases of the cervix uteri may be discussed under the following headings: Inflammation Polyps Carcinoma Inflammation Acute Acute cervicitis may be caused by non-specific bacterial infection or may arise secondary to specific sexually transmitted diseases e.g. gonorrhoea, herpes, trichomonas, chlamydia etc. The pathological appearances are those of the standard acute inflammatory process as seen elsewhere in the body. Chronic Chronic cervicitis is ubiquitous in older women and the severity varies considerably. Squamous metaplasia of the endocervical epithelium (mucin-secreting columnar) often accompanies chronic inflammation. The inflammatory process may lead to occlusion of the endocervical glands (these are really crypts and not true glands) with retention of secretions, dilatation and formation of cysts known as nabothian cysts (seen clinically as nabothian follicles). Polyps Endocervical polyps are really overgrown folds of endocervical mucosa. They often contain cystically dilated glands in a vascular, fibrous stroma and may ulcerate and bleed. They are not premalignant.  HYPERLINK "http://www.gfmer.ch/Books/Cervical_cancer_modules/Images/MII5.jpg" Gross (clinical) endocervical polyp Carcinoma Cancer of the cervix is thought to begin in a single cell (or clone of cells) at the squamocolumnar transformation zone (TZ). Cervical cancer has two phases: Pre-invasive disease (Cervical Intraepithelial Neoplasia) Invasive disease. Cervical Intraepithelial Neoplasia (CIN) This term is now used to characterize precancer of the cervix and describes the aberrant changes occurring in the cervical epithelium as it becomes neoplastic and is replaced by abnormal cells. These abnormal cells show loss of normal maturation, loss of polarity, excessive and abnormal mitotic activity, increased nuclear-cytoplasmic ratio and nuclear hyperchromasia and pleomorphism. The term dysplasia was used (and still is by some people) to describe these changes in the past and cervical dysplasia is graded as follows: Mild dysplasia the abnormal cells are predominantly confined to the lower third of the epithelium Moderate dysplasia the abnormal cells extend into the middle third of the epithelium Severe or marked dysplasia the abnormal cells extend into the upper third of the epithelium In situ carcinoma the full thickness of the epithelium is replaced by the abnormal cells. Over the past 2 decades, this "dysplasia" classification of premalignant cervical disease fell from favour because: 1) There was a tendency to treat different grades of dysplasia as separate entities rather than as stages of a disease that may co-exist and convert from one to another. 2) Severe dysplasia and in situ carcinoma are difficult to separate objectively in histology sections and behave biologically as one and the same entity. The term cervical intraepithelial neoplasia (CIN) was introduced to encompass the whole spectrum of premalignant change in the cervical epithelium, and its usage implies a unified concept of a single disease process. CIN is divided into three grades: CIN I lesions previously described as mild dysplasia CIN II lesions previously described as moderate dysplasia CIN III lesions previously classified as severe dysplasia or in situ carcinoma. Subsequent to the CIN nomenclature, another classification system was introduced in the USA the Bethesda System which uses only two grades of abnormality known as: LSIL low-grade squamous intraepithelial lesion (corresponding to CIN I) HSIL high-grade squamous intraepithelial lesion (corresponding to CIN II or CIN III). DysplasiaCINBethesdaMildILSILModerateIIHSILSevere/Ca-in situIIIHSIL The CIN concept seeks to underscore the fact that premalignant disease of the cervix is a continuum and is neoplastic change that starts from one end of a spectrum and may progress to in situ carcinoma. Most CIN lesions do NOT progress to invasive cancer, but all tend to be treated as potential cancers as it is not possible to predict clinically or histologically which lesion will progress. We do know, however, that the chances of progression depend heavily on the grade of CIN the higher the grade, the greater the probability of progression will be (see below under HPVs for link to HPV type). Figures vary, but it has been reported that spontaneous regression occurs in about 60% of CIN I, 40% of CIN II 33% of CIN III lesions Progression to CIN III occurs in about 10% of CIN I 20% of CIN II lesions. The time taken for progression is not known and there is probably marked variation in individual cases, but the progression time from CIN I to CIN III has been estimated to have a mean duration of 12 to 15 years. It is thought that only a small minority of CIN III lesions will progress to invasive cancer, usually in the range of 1-5%. Therefore, in any individual patient, any CINIII lesion has to be regarded as potentially invasive and must be managed appropriately. Aetiology and Epidemiology of Cervical Carcinoma Epidemiological studies have demonstrated a positive association between squamous cell carcinoma of the cervix and the following factors: Early age of first coitus Multiple sexual partners AND/OR a male partner with multiple previous sexual partners Multiparity Low socio-economic status Cigarette smoking A history of STDs, especially genital warts Immunosuppression from any cause (including HIV infection) It had always been clear that the epidemiological profile of cervical cancer fit that of a sexually transmitted disease, and it had long been postulated that a carcinogen (or carcinogens) was transmitted sexually from the man to the woman, a hypothesis made much more plausible when it was also noted that there was a higher incidence of cervical cancer in women whose sexual partners had a history of: Recurrent STD's and /or Poor genital hygiene and/or Carcinoma of the penis Over the years, various agents had been implicated as this carcinogenic factor, including gonococcus, treponema pallidum, chlamydia and HSV, but none of these were satisfactorily substantiated. In the 1970s, a high prevalence of cervical HPV infection was noted in cytological and histological samples of women with CIN and invasive cancer of the cervix, leading to HPV being implicated as the sexually transmitted causative agent in CIN/cervical cancer. HUMAN PAPILLOMA VIRUSES (HPVs) These are DNA tumour viruses that predominantly affect skin and mucous membranes producing characteristic epithelial proliferations at the sites of infection. There are many serotypes, with most being relatively site-specific when they infect. Those that frequent the genitals are known as ano-genital HPVs. Most anogenital HPV infections are transient and self-limiting, and the majority of infected women will clear the infection within two years. HPVs are classified into two main types: low-risk those not associated with cervical carcinoma high-risk those associated with cervical carcinoma. Low-risk types These are typified by types 6 and 11, and are associated with low-grade lesions, i.e. CIN I (LSIL), which may manifest themselves as condylomas, e.g. condylomata acuminata or flat condylomas. When these HPVs infect the cervical epithelium, the viral DNA does not integrate into the genome of the host cell, but exists as free extrachromosomal forms within the nucleus called episomes. High-risk types These are typified by types 16 and 18 and are associated with high-grade lesions, i.e. CIN II & III (HSIL), and invasive carcinoma. When these HPVs infect the cervical epithelium, the viral DNA integrates into the host genome and viral DNA replicates independently of host DNA synthesis. Viral DNA integration disrupts the HPV E2 gene which results in the loss of normal E2 down-regulation of the E6 and E7 genes. The E6 and E7 genes encode for proteins that: Inactivate or block the host tumour suppressor genes p53 and RB1 in the host cells, and Activate cell cycle-related genes e.g. cyclin E, causing uncontrolled cellular proliferation. This combination [plus or minus a co-factor(s)] sets the stage for malignant transformation of the cervical epithelium. In summary, the epidemiological studies now suggest the following natural history. When women begin sexual intercourse in their teens or twenties, HPV infection is a common result. Most women develop no clinical evidence of disease (latent infection) and eventually suppress and lose the infection. Others get low-grade lesions (infection with low-risk HPVs) many of which regress spontaneously (? via innate host defence mechanisms). However, a minority of women develops persistent infection (? due to an inadequate immune response) and if these infections are with high-risk HPV types then, perhaps with the facilitation of genetic factors and other co-factors such as cigarette smoking, progression to high-grade CIN may occur. To put things in perspective however, please note that only about 3% to 4% of women infected with HPV worldwide go on to develop cervical cancer. Incidence and Prevalence The Jamaican Cancer Registry, which documents malignancies in Kingston and St. Andrew, gives the following statistics for carcinoma of the cervix and for breast cancer the top two cancers in Jamaican women (figures quoted as crude incidence rate per 100,000 women per annum): YearsBreast CancerInvasive Cervical CancerIn situ Cervical CancerTotal Cervix Cancer1978-198228.620.510.631.11983-198732.221.515.637.11988-199236.021.940.4 62.31993-199735.021.030.0 51.0 The incidence of breast cancer has been consistently higher than that of invasive cervical cancer. The combined figure for cervix is not used as in situ cervical cancer is not biologically active, i.e. is not locally destructive and does not metastasize. Note also that the overall incidence of invasive cervical cancer has remained virtually unchanged. Squamous Cell Carcinoma The majority (approx. 90%) of cervical carcinomas are squamous cell carcinomas (SCC). Invasive SCCs are classified as (1) Microinvasive or (2) Invasive (frankly). Microinvasive Microinvasive carcinoma (MICA) is an invasive carcinoma, i.e. the malignant cells have broken through the basement membrane to invade the underlying stroma, but the neoplasm by definition is deemed to be smaller than a frankly invasive carcinoma. There are two commonly used definitions of MICA. The Society of Gynecological Oncologists (SGO) in the USA define MICA as an invasive lesion with a depth of stromal invasion of 3 mm or less below the basement membrane of the epithelium, in which there is no evidence of vascular invasion. The presence of vascular invasion by tumour cells classifies the tumour as a frankly invasive carcinoma no matter the depth of stromal penetration. The International Federation of Gynecologists and Obstetricians (FIGO) define MICA as an invasive lesion than invades to a depth of not more than 5 mm below the basement membrane with a horizontal spread not exceeding 7 mm. MICA, although being invasive,has a good prognosis that is just slightly worse than that of CIN III. Invasive Grossly, these may be polypoid (fungating), papillary, nodular or ulcerating, and histologically they show varying degrees of differentiation. Local invasion (direct extension) involves the corpus uteri, vagina, parametrium, bladder and rectum. Metastases are via lymphatics to pelvic, inguinal, iliac and para-aortic lymph nodes. Haematogenous spread to liver, lungs and bone occurs, but at a very late stage. Death is more often due to the effects of local invasion (ureters, bladder, rectum etc.) rather than to metastases, and most deaths are due to uraemia secondary to ureteric obstruction.  HYPERLINK "http://www.gfmer.ch/Books/Cervical_cancer_modules/Images/MI18.jpg" Colposcopic picture of ca cervix  HYPERLINK "http://www.gfmer.ch/Books/Cervical_cancer_modules/Images/MI15.jpg" Clinical picture of ca cervix Treatment and prognosis depends on the stage of the tumour. A simplified clinical staging system is as follows: Stage 0: Carcinoma in situ (CIN III) Stage I: Carcinoma confined to the cervix Stage Ia: Microinvasive carcinoma Stage 1b: Invasive (frankly) Stage II: Extension beyond the cervix into the upper two-thirds of the vagina Stage III: Extension to the pelvic wall and/or lower third of the vagina Stage IV: Extension beyond the pelvis or into urinary bladder or rectum Treatment/Prognosis The gynaecologists will cover this area comprehensively. The following is a mere synopsis. CIN is usually removed by any of a variety of methods including cryocautery, laser therapy, loop diathermy or a cone biopsy. Patients are followed up by Pap smears and/or colposcopy to exclude recurrence. Microinvasive carcinoma is usually treated by total hysterectomy. Other stage I tumours are treated by radical hysterectomy or radiotherapy. Stages II IV are treated by radiotherapy. The 5-year survival for stage I carcinomas with negative lymph nodes is 90%, and this falls off to about 70% for stage II, 30% for stage III and 10% for stage IV. Cervical Screening By Cervical (Pap) Smears Cytological screening for cervical cancer by the use of the Pap smear has revolutionized investigation of the disease. In 1928 Dr. George Papanicolaou, a pathologist, presented his findings that cancer cells could be found in the vaginal fluid of women with cancer of the cervix. In the mid-1940s, Dr. J. Ernest Ayre described the method we know today as the Pap smear when instead of studying vaginal pool secretions like Papanicolaou, he used a spatula to directly scrape cells from the cervix. Pap smear screening for cancer of the cervix became widespread by the 1950s, and in countries where it has been used effectively it has dramatically reduced the number of deaths from this disease because of early detection of CIN lesions. A special wooden spatula (Ayre's spatula), or some similar device, is used to gently scrape the superficial cells from the TZ and adjoining ectocervix. This material is smeared on a glass slide, stained with the Papanicolaou stain and examined under the microscope for the cellular features of CIN.  This photomicrograph shows numerous koilocytes on a pap smear indicative of HPV infection. The arrow points to a binucleate koilocyte. Abnormalities may be followed up by colposcopy. The colposcope is an instrument used by the gynaecologist to examine the cervix grossly. It magnifies the cervix to an extent whereby abnormal vascular and epithelial patterns characteristic of varying grades of CIN may be diagnosed. These areas are then biopsied for histological confirmation. Adenocarcinoma These account for about 5-10% of cervical cancer. The risk factors are not as clearly defined as for squamous cancer but a relatively strong association with HPV infection has been reported. They are adenocarcinomas of varying degrees of differentiation. Prognosis is related to the stage of the lesion and tends to be worse than the corresponding stage for squamous cell carcinoma because of the tendency for the lesion to spread to lymph nodes early. Reference websites: Pictures of various areas of gynaecological pathology:  HYPERLINK "http://www-medlib.med.utah.edu/WebPath/ORGAN.html" http://www-medlib.med.utah.edu/WebPath/ORGAN.html, then click on female genital tract pathology Lectures on gynaecological pathology:  HYPERLINK "http://cats.med.uvm.edu/cats_teachingmod/pathology/path302/gyn/gynel/cervix/gyncervi.htm#anchor19391320"  http://cats.med.uvm.edu/cats_teachingmod/pathology/path302/gyn/home/gynindex.html Tumours of female reproductive organs:  HYPERLINK "http://www.bioscience.org/atlases/tumpath/freprod/freprod.htm" http://www.bioscience.org/atlases/tumpath/freprod/freprod.htm CTE/cte/Feb 2007   PAGE  PAGE 12 Page  PAGE 1 of 8 46;Yi ϢzcO;($h\%h\%@CJKHOJQJaJ'h\%h\%5@CJKHOJQJaJ'h\%h\%@CJKHOJQJ\aJ-h\%h\%56@CJKHOJQJ]aJ%h\%h\%56@KHOJQJ])h\%5@CJKHOJQJaJmHsH/h\%h 5@CJKHOJQJaJmHsH)h 5@CJKHOJQJaJmHsH/h\%h\%5@CJKHOJQJaJmHsH/h\%h 5@CJKHOJQJaJmHsH 56Y i u v } ~ & F 0 0 H@&$ Ha$ H@&gd\% & F H@&gd\%$ 0h^ha$gd\% $ 0a$gd\% $ H@&a$mnni j r s t w | } ) * 3 4 ϳ堊vcP@c@c@c@c0hS@CJKHOJQJaJh5@CJKHOJQJaJ$hb(4h#W@CJKHOJQJaJ$hb(4h @CJKHOJQJaJ'h\%h 5@CJKHOJQJaJ*h\%h 5>*@CJKHOJQJaJ$h\%h @CJKHOJQJaJ6jhb(4h >*@CJKHOJQJUaJ*h\%h >*@CJKHOJQJaJ3jhb(4h >*@CJKHOJQJUaJ * 5 6 7 > ? z M t u v OMNmn 0@& 0 H@& & F 04 5 6 7 8 > ? Y x  L Y ] c ~~~~h~~UA'jh+d@CJKHOJQJUaJ$h]h]@CJKHOJQJaJ*hb(4h 5@CJKHOJQJ\aJh 9@CJKHOJQJaJh5@CJKHOJQJaJ*hb(4h#W56@CJKHOJQJaJ0h\%h 56:>*@CJKHOJQJaJh 3@CJKHOJQJaJhS@CJKHOJQJaJ$hb(4h @CJKHOJQJaJ M N O r s t u v w ­zgN:N$*hb(4h#W56@CJKHOJQJaJ'h\%h :@CJKHOJQJaJ0h\%h 56:>*@CJKHOJQJaJ$hb(4h @CJKHOJQJaJ$h]h 9@CJKHOJQJaJh]@CJKHOJQJaJh @CJKHOJQJaJ(h+dh+d0J#@CJKHOJQJaJ'jh+d@CJKHOJQJUaJ3jdh+dh*8G@CJKHOJQJUaJh+d@CJKHOJQJaJ 5VLMNͽoYEE2$hb(4h]@CJKHOJQJaJ'hb(4h 6@CJKHOJQJaJ*hb(4h\%5@CJKHOJQJ\aJ'h 5>*@CJKHOJQJ\aJ-hb(4h 5>*@CJKHOJQJ\aJ$hb(4h 3@CJKHOJQJaJh 3@CJKHOJQJaJh\%@CJKHOJQJaJh @CJKHOJQJaJh 9@CJKHOJQJaJ$hb(4h @CJKHOJQJaJNlmnz{567zfV*@CJKHOJQJ\aJ-hb(4h 5>*@CJKHOJQJ\aJn%w {PfTIJ 0gd\% & F 0 & F 0@&gd\%$a$ 07NOPQ'״׊ā{t[H8Hh 3@CJKHOJQJaJ$hb(4h @CJKHOJQJaJ0hb(4h 56@CJKHOJQJ\]aJ h\%h\% h aJhb(4h aJh\%@CJKHOJQJaJ3jh+dh*8G@CJKHOJQJUaJh+d@CJKHOJQJaJ$h+dh+d@CJKHOJQJaJ'jh+d@CJKHOJQJUaJ(h+dh+d0J#@CJKHOJQJaJ'()}>?@杄p\L2\3jh+dh*8G@CJKHOJQJUaJh+d@CJKHOJQJaJ'jh+d@CJKHOJQJUaJ'hb(4h 6@CJKHOJQJaJ0hb(4h 56@CJKHOJQJ\]aJ$hb(4h @CJKHOJQJaJ h+dh+d0J#CJOJQJaJ+jh+dh*8GCJOJQJUaJh+dh+dCJOJQJaJ%jh+dh+dCJOJQJUaJ h+dh+d@defnST~īěyrb[H9h*8Gh*8GCJOJQJaJ%jh*8Gh*8GCJOJQJUaJ h*8Gh*8Gh 3@CJKHOJQJaJ h\%h\% h aJhb(4h aJ$hb(4h\%@CJKHOJQJaJh @CJKHOJQJaJ0hb(4h 56@CJKHOJQJ\]aJ$hb(4h @CJKHOJQJaJ'jh+d@CJKHOJQJUaJ(h+dh+d0J#@CJKHOJQJaJ~HIJKֲp_N_>81 h\%h\% h aJ *hb(4h CJOJQJaJ hb(4hi}CJKHOJQJaJ hb(4h CJKHOJQJaJ-hb(4h\%5>*@CJKHOJQJ\aJ'h 5>*@CJKHOJQJ\aJ-hb(4h 5>*@CJKHOJQJ\aJ$h*8Gh @CJKHOJQJaJ h*8Gh*8G0J#CJOJQJaJ%jh*8Gh*8GCJOJQJUaJ+jh*8Gh*8GCJOJQJUaJJKUV]|2!  %&F !!!$"c#d#$!$a$ 0 0@&gd\%KUV\VZ'NTbdy{|23ƳtdtttTd;0jh*8Gh*8G>*@CJKHOJQJUaJh @CJKHOJQJaJh 3@CJKHOJQJaJ'hb(4h 5@CJKHOJQJaJ-hb(4h 56@CJKHOJQJ]aJ'hb(4h @CJKHOJQJ\aJ$hb(4h @CJKHOJQJaJ*hb(4h 5>*@CJKHOJQJaJ*hb(4hh5>*@CJKHOJQJaJh\%h :>*KHaJ3|}~϶ziMz8z$'hC}hC}>*@CJKHOJQJaJ(hC}hC}0J#@CJKHOJQJaJ6jhC}h.%3>*@CJKHOJQJUaJ!hC}>*@CJKHOJQJaJ*jhC}>*@CJKHOJQJUaJ!h8>*@CJKHOJQJaJ(h*8Gh*8G0J#@CJKHOJQJaJ0jh*8Gh*8G>*@CJKHOJQJUaJ6jh*8Gh*8G>*@CJKHOJQJUaJ'h*8Gh*8G>*@CJKHOJQJaJ   $%&29=E$ D F K !!(!!ԮqaqMqqqMMM'hb(4h 5@CJKHOJQJaJh 3@CJKHOJQJaJ$hb(4hfg@CJKHOJQJaJ*hb(4h 5@CJKHOJQJ\aJ'hb(4h?5@CJKHOJQJaJ$h 5>*@CJKHOJQJaJ$hb(4h @CJKHOJQJaJ*hb(4h 5>*@CJKHOJQJaJ*h8hc5>*@CJKHOJQJaJ!!! " " """#"$""#c#d#m###̲ܝ܊ulV?,$hb(4h @CJKHOJQJaJ-hb(4h 5>*@CJKHOJQJ\aJ*hb(4h 5>*@CJKHOJQJaJhb(4hfgaJhb(4h 5\aJhb(4h aJ$hHhH@CJKHOJQJaJ(hHhH0J#@CJKHOJQJaJ3jhHh.%3@CJKHOJQJUaJhH@CJKHOJQJaJ'jhH@CJKHOJQJUaJh @CJKHOJQJaJ##$$$?%@%A%k%l%n%o%%%%dztdPd6P3j h?h.%3@CJKHOJQJUaJ'jh?@CJKHOJQJUaJh?@CJKHOJQJaJ(hHhH0J#@CJKHOJQJaJ3j hHh.%3@CJKHOJQJUaJhH@CJKHOJQJaJ'jhH@CJKHOJQJUaJh @CJKHOJQJaJ$hb(4h @CJKHOJQJaJ*hb(4h 56@CJKHOJQJaJ%&&&&&&&&''''''V(W(a(b(((Ĵ{{hQ;h*hb(4h 56@CJKHOJQJaJ-hb(4h 56>*@CJKHOJQJaJ$hb(4hfg@CJKHOJQJaJ*hb(4h 5@CJKHOJQJ\aJh 3@CJKHOJQJaJ$hb(4h @CJKHOJQJaJh?@CJKHOJQJaJ$h?hH@CJKHOJQJaJ'jh?@CJKHOJQJUaJ(h?h?0J#@CJKHOJQJaJ$&&&&'V(W((()))))++),*,,,--v.w.... H@& 0(()))))))*1*4*E*H*X*[*++ȸ؏|iUE5h:4@CJKHOJQJaJh @CJKHOJQJaJ'hb(4h 5@CJKHOJQJaJ$hb(4hfg@CJKHOJQJaJ$h\%h @CJKHOJQJaJ*h\%h 5>*@CJKHOJQJaJ$hb(4h?@CJKHOJQJaJh\%@CJKHOJQJaJh @CJKHOJQJaJ$hb(4h @CJKHOJQJaJ'hb(4h >*@CJKHOJQJaJ+++(,),*,A,,,,,--->-v.w........ııı|lYC*h\%h 5>*@CJKHOJQJaJ$hb(4h?@CJKHOJQJaJh\%@CJKHOJQJaJh @CJKHOJQJaJ'hb(4h 5@CJKHOJQJaJ!h 5@CJKHOJQJaJ$hb(4h @CJKHOJQJaJ$hb(4h @CJKHOJQJaJ*hb(4h 5@CJKHOJQJ\aJ$h 5@CJKHOJQJ\aJ... /`/m/t/~////L0000222333`4444 & F 0 0 & F 0gde{$a$$ Ha$ 0@&.../// /`/t/~///ӽӍ~n[D--hb(4h 56>*@CJKHOJQJaJ-hb(4h 56>*@CJKHOJQJaJ$hb(4h @CJKHOJQJaJhe{@CJKHOJQJaJhb(4h 56\]aJ'h\%h >*@CJKHOJQJaJ6j h\%h >*@CJKHOJQJUaJ*h\%h >*@CJKHOJQJaJ3jh\%h >*@CJKHOJQJUaJ$h\%5>*@CJKHOJQJaJ ////K0L0000222^3_3`3333ԭpiVG1V+jq hC'h.%3CJOJQJUaJhC'hC'CJOJQJaJ%jhC'hC'CJOJQJUaJ hC'hC'-hb(4h 56>*@CJKHOJQJaJ*hb(4h 5>*@CJKHOJQJaJhe{@CJKHOJQJaJ$hb(4h @CJKHOJQJaJ'hb(4h 5@CJKHOJQJaJ*hb(4h 5>*@CJKHOJQJaJ*hb(4h 56@CJKHOJQJaJ333333_4444444445ɶycJ4*hb(4h 6@CJKHOJQJ]aJ0hb(4h 56>*@CJKHOJQJ]aJ*hb(4h 5>*@CJKHOJQJaJ*hb(4h 5>*@CJKHOJQJaJhe{@CJKHOJQJaJ-hb(4h 56>*@CJKHOJQJaJ$hb(4h @CJKHOJQJaJ$hC'h @CJKHOJQJaJ%jhC'hC'CJOJQJUaJ hC'hC'0J#CJOJQJaJ44444 7q77&88889?:@:=;t;;<<<<N=O=P= & F 0 & F 0 & F 0 05 555556666 77*7q7777777777&87888H:I:q:=;B;t;z;;;<<ڴڠڠڇڠڠsڠ____'hb(4h 5@CJKHOJQJaJ'hb(4h @CJKHOJQJ]aJ0hb(4h 56@CJKHOJQJ\]aJ'hb(4h 6@CJKHOJQJaJ*hb(4h 5>*@CJKHOJQJaJhGE|@CJKHOJQJaJ$hb(4h @CJKHOJQJaJ$hb(4h @CJKHOJQJaJ%<9<^<w<<<<<N=O=P=g=h=l=m=n=o=s=u=}=~============??ݹrbh?@CJKHOJQJaJ$hb(4h_@CJKHOJQJaJh_@CJKHOJQJaJ'h h_5@CJKHOJQJaJh @CJKHOJQJaJh @CJKHOJQJaJ'hb(4h 5@CJKHOJQJaJ$hb(4h @CJKHOJQJaJhGE|@CJKHOJQJaJ!P=Z=^=g= 0$Ifl& 0$Ifl& 0$Ifl&g=h=m=o=L8$ 0$Ifa$gd l& 0$Ifl&kdf $$IflF  t06    44 la po=t=u=~===M3$ 0$Ifa$gd l&kd$$IflF t06    44 la p 0$Ifl&=====aM3M$ 0$Ifa$gd l& 0$Ifl&kdt$$IflF t06    44 la p====0?@Y@g@u@@a[[[[[OOO & F 0gdGE| 0kd$$IflF t06    44 la p ?@@@X@Y@\@g@j@t@u@x@@@@@@@@@@AAA B$B&B+B,B-B.BB׷׷׷׷׷׏|hXhRt@CJKHOJQJaJ'hGE|h?5@CJKHOJQJaJ$hGE|h?@CJKHOJQJaJ'hGE|h 5@CJKHOJQJaJ'h?h 5@CJKHOJQJaJhGE|@CJKHOJQJaJh?@CJKHOJQJaJ$hb(4h @CJKHOJQJaJ*h?h?56@CJKHOJQJaJ@@@@@@AA.BBBBqCCCCDDFDDDF.FKF & F 0 & F 0gdRt & F 0 0 & F 0gdGE| 0gdGE|BBBBBpCqCCCCCCCCCDDDDEDFDdz}jYGYj5j}j}j}j"hRth CJOJQJ\]aJ#hRth 5CJKHOJQJaJ hRth CJKHOJQJaJ$hRthRt@CJKHOJQJaJ$hRth @CJKHOJQJaJhRt@CJKHOJQJaJ$hb(4h @CJKHOJQJaJ'hb(4h 5@CJKHOJQJaJ*hb(4h 5>*@CJKHOJQJaJ$hb(4h_@CJKHOJQJaJh @CJKHOJQJaJFDDEFKFaFbFcF$G%GG*H+H,H-HLHMHHH&ICIʺڗڄq_F_<5<5 hE]aJhbzhy]aJ0hbzhy5>*@CJKHOJQJ\]aJ"hbzhy@KHOJQJ\]$hbzh @CJKHOJQJaJ$hbzhy@CJKHOJQJaJhRt@CJKHOJQJaJ$hbzh>@CJKHOJQJaJh @CJKHOJQJaJh>@CJKHOJQJaJ$hbzh @CJKHOJQJaJ$hRth @CJKHOJQJaJKFbFcF%G+H,H-HLHMHHBIIIJ=JwJJJJKFLGLXL"gd4" & FgdE"gdy $ 0a$gdy 0 0h^hgd> & F 0CIIIIIJJJ?JFJGJmJvJwJxJJJJJJJJJJJKFKRKlKKKKKLLL2LELGLVLWLXLtL}LȼԼȳԩԩԓ}th(5]aJh4h 5]aJhbzh(]aJ h[]aJ h4aJhbzh4aJhbzh4]aJh45]aJh4hsE5]aJh4h45]aJ h4]aJ hE]aJhEhsE5]aJ hsE]aJhbzhy]aJ-}LLL=M|M}MN NNNNN)NNNOOOO&O/OZO[O\OfOPPPPPQQݸzl]Qh CJOJQJaJhb(4h CJOJQJaJh1{LCJKHOJQJaJh CJKHOJQJaJ hb(4h CJKHOJQJaJ&hb(4h 5>*CJKHOJQJaJhyhyCJaJhyhy]aJhbzh ]aJhbzh1{L]aJ hE]aJhbzhy]aJ h[]aJh4h4]aJ h4]aJXLLL}MMM*NNNN[O\OQQ;R*@CJKHOJQJaJ*hb(4h 5>*@CJKHOJQJaJ$h.5>*@CJKHOJQJaJ*hb(4h 5>*@CJKHOJQJaJ(h7h75B*CJOJQJaJphh7h75CJOJQJaJh7h[5CJOJQJaJh CJOJQJaJh[CJOJQJaJhb(4h CJOJQJaJTT.TFTZT[T3kdX$$Iflrz 6>J  6`l064 la 0$l&`#$/Ifgd TZT[TeTzTTTTTUUUQUZUlVmVVVV*W+W9W:WװzpcYRI@9 hbzh hbzh aJhb(4h aJ h h h 6\]aJhb(4h 6\]aJh 6\]aJ*hb(4h 5@CJKHOJQJ\aJh @CJKHOJQJaJh @CJKHOJQJaJ$hb(4h @CJKHOJQJaJ'hb(4h @CJKHOJQJ\aJ$hb(4h @CJKHOJQJaJ*hb(4h 5@CJKHOJQJ\aJ[TeTjToTtTyT 0$l&`#$/Ifgd yTzTTTTTI3333 0$l&`#$/Ifgd kdB$$Iflrz 6>J  6`l064 laTTTTTT3kd,$$Iflrz 6>J  6`l064 la 0$l&`#$/Ifgd TTTTTT3kd$$Iflrz 6>J  6`l064 la 0$l&`#$/Ifgd TTTTTU3- 0kd$$Iflrz 6>J  6`l064 la 0$l&`#$/Ifgd UUUUUUUUlVmVVV*W+W9W:W4X5XfXYZZ3[4[=[>[] & F 0gdbzgd  0:WYWqWxWWWWfXXXXX*YUYYYYYY2ZoZZZZZZ2[3[4[<[ƳuڳڳڋeULhb(4h aJhbz@CJKHOJQJaJh @CJKHOJQJaJ*hbzh 5@CJKHOJQJ\aJ'hbzhbz5@CJKHOJQJaJ'hbzh 5@CJKHOJQJaJ$hbzhbz@CJKHOJQJaJ'hbzh;d$5@CJKHOJQJaJ$hbzh @CJKHOJQJaJ$hbzh;d$@CJKHOJQJaJ<[=[>[]]]]]^^^ ^X^Y^Z^w^x^y^z^^̼̍}̼c̍S@$h>h>@CJKHOJQJaJh>@CJKHOJQJaJ3jhrch.%3@CJKHOJQJUaJh @CJKHOJQJaJ(hrchrc0J#@CJKHOJQJaJ3jhrch.%3@CJKHOJQJUaJhrc@CJKHOJQJaJ'jhrc@CJKHOJQJUaJ$hb(4h @CJKHOJQJaJ h h h aJ]^y^z^^_:___|__`h`i`}`~``aa5bcbdbc 0h^h & F 0 & F 0gd ^ & F 0 & F 0 0^^__:_C___h_|____``h`|`}`~```aaaa5bDbcbdbcc c c5c6c7cϹ|lf]W h aJhb(4h aJ h XaJh @CJKHOJQJaJh @CJKHOJQJaJ h h h CJaJhb(4h CJaJ$hb(4h @CJKHOJQJaJ*hb(4h 5@CJKHOJQJ\aJ,hb(4h @CJKHOJQJaJmHsH2hb(4h 5@CJKHOJQJ\aJmHsH"cc c c6c7cfDgEgHgIgg'i(i7iijjkkKkkklh^hgd$G & F gd$Ggd  0gd  0h^h7ccffCgEgFgGgIgxggg'i(i7ijjkueuYF7hb(4hb(4CJOJQJaJ$hb(4h @CJKHOJQJaJhb(4h 6]aJhsEhsE56KHOJQJhsEhrc56KHOJQJ)jhrchrcCJKHOJQJUaJ.jhrcCJKHOJQJUaJmHnHuhrcCJKHOJQJaJ hb(4h CJKHOJQJaJhb(4h CJKHaJhb(4h CJOJQJaJ$hb(4h @CJKHOJQJaJk kkkk k1kAkJkKkLkQkRkkkkkkkkkkkkkk"lӸӥo`PCPCh$G5CJOJQJaJhb(4h 5CJOJQJaJhb(4hgCJOJQJaJ hb(4hb(40J#CJOJQJaJ+jhb(4hb(4CJOJQJUaJhb(4hb(4CJOJQJaJ%jhb(4hb(4CJOJQJUaJh CJOJQJaJhb(4h CJOJQJaJh$GCJOJQJaJh h 5CJOJQJaJh hb(45CJOJQJaJ"l$l%lllllllllmm+mhmjmkmlmmmmmҼᵤ|papK|:|pa hlDh0J#CJOJQJaJ+jEhlDhCJOJQJUaJhhCJOJQJaJhCJOJQJaJjhCJOJQJUaJh CJOJQJaJhb(4CJOJQJaJ h h 0J#CJOJQJaJ h h +j,h$Ghb(4CJOJQJUaJh$Ghb(4CJOJQJaJ%jh$Ghb(4CJOJQJUaJh$GCJOJQJaJllmmmmmmmmmmmmmmmmmmmmmh]h&`#$dgdV,:$a$ 0gd Qh^hgd  & Fgd Qgd$GmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmnnϼvvkvghNahGE|hmHnHujh3Uh h3hhE0JmHnHu h30Jjh30JU h3CJjh3Uh3jh3CJU$hb(4h @CJKHOJQJaJ h7hV,: h7h hEh7h7@KHOJQJh @CJKHOJQJaJ&mmmmmmmnnnnn 0 $a$h]h&`#$ nnn$hb(4h @CJKHOJQJaJh :....()()))() 0000P8$BP/ =!"#$% dD phoenix WCHoDyK yK http://www.brooksidepress.org/Products/Military_OBGYN/Textbook/Vulva/Bartholin.htmDyK yK http://www.brooksidepress.org/Products/OBGYN_101/MyDocuments4/Text/Vulva/LGV1640.jpgDyK yK http://www.brooksidepress.org/Products/OBGYN_101/MyDocuments4/Text/Vulva/LGV.jpgDyK yK http://www.brooksidepress.org/Products/OBGYN_101/MyDocuments4/Text/Vulva/1syph.jpgDyK yK http://www.brooksidepress.org/Products/OBGYN_101/MyDocuments4/Text/Vulva/2syphb.jpg/DyK yK http://www.brooksidepress.org/Products/OBGYN_101/MyDocuments4/Text/Vulva/HerpesVulvitis640.jpgDyK yK xhttp://www.phac-aspc.gc.ca/slm-maa/slides/hpv/pages/16.htmlDyK yK thttp://www.visualsunlimited.com/browse/vu364/vu36461.html DyK yK http://www.brooksidepress.org/Products/Military_OBGYN/Textbook/Vulva/vin3.jpgDyK yK http://www.brooksidepress.org/Products/Military_OBGYN/Textbook/Vulva/vulvaca.jpgDyK yK http://www.brooksidepress.org/Products/Military_OBGYN/Textbook/Vulva/SqCaVulva.jpgdD phoenix LOCALCOMPACT EXDyK yK http://www.gfmer.ch/Books/Cervical_cancer_modules/Images/MII5.jpg$$If !vh5255#v2#v#v:V&l  t655a p$$If !vh5255#v2#v#v:V&l t655a p$$If !vh5255#v2#v#v:V&l t655a p$$If !vh5255#v2#v#v:V&l t655a $$If!vh55555 #v#v#v#v#v :V l 6`l0655555 4$$If!vh55555 #v#v#v#v#v :V l 6`l0655555 4$$If!vh55555 #v#v#v#v#v :V l 6`l0655555 4$$If!vh55555 #v#v#v#v#v :V l 6`l0655555 4$$If!vh55555 #v#v#v#v#v :V l 6`l0655555 4DyK yK http://www.gfmer.ch/Books/Cervical_cancer_modules/Images/MI18.jpgDyK yK http://www.gfmer.ch/Books/Cervical_cancer_modules/Images/MI15.jpgDd V  C 2AKoilocytes11Rqb0Š.SG5W/MFEb0Š.SG5W/EExifII*  (1 2i NIKONE995,,E995v1.62003:10:15 13:43:17BJ"'d0210Rfz   |}0100v " 2003:10:15 13:43:172003:10:15 13:43:17 fn($ ,,R980100   ^COLORBASIC AUTO AUTO AF-C "AUTO AUTO OFF dd OFF ='4()S()S I)42R""""3333R I(4C!a1 pFRhqRed dG  {~   eC!PrintIM0100 ^  ' ''''^''''>F(=8B4,,  .9)+".C;GFB;A@JTkZJOeP@A]~^enrwywHYtkuws77sMAMssssssssssssssssssssssssssssssssssssssssssssssssss77sMAMssssssssssssssssssssssssssssssssssssssssssssssssss }!1AQa"q2#BR$3br %&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz w!1AQaq"2B #3Rbr $4%&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyzx! ?Kq*}jgpc`֩_j' JIs;#;f9g?/9FZ<3~)BBeNToC)nWE.=iLcZ]w*'zlB%,"hznJ)0g+T{Ne 0IrOSU9m3kX*~r%V<%^85jZ|ܖUI"jҵ1®T7 =Nzެ;26n~dX#HRweuY%W; =)Ĥ>Oa1ǵ&:=In6fjs[b̮88F[_D9K3."8UIEJ+5##_vp#'uQybksT`$(NgG䎔jƖ*Lۚ,Q+*ae*/JKsKG[D=sBobZ[M+QB%@Rʣ-y4Xkh)u![Byq\mXٖqQizg!GCO.ڳ%$!+ɪ0M;6&5楍N0z̞dCJ\[IrI-ͅ5IU.bXP(==j;ͦ,3/Նy5fV4r.ԛ4^Il4Ĩ08ph$XQR RM4DpFr UU m;&a*ܱ7S{jB#Ls*]UhRINUt: 4z!_.:'F03SSO}QhȤ3xY.ܨB\W 1يMNiG_[(GjX<755C$\犭yX6Z'TMhZW4RT7O2qZV6jdCFbsU{U}+TCLmҥݢ|mF MڃT6Wvb2FijEnZ"@MVSЊ(qUYݚ?)KiK[ j7 ϼOSVl 7o'ƭ] ۊm] ݹmH`Z3e[UUOa)sMꀮ,[whr G$sNSID9ObMa"Is k{։DX[KAGL)6*g=c ާw>>9m%Kad ڋl` P'=@%9n-j=TFpfKpHke9{ՇeBۙcOEtwq;łR$M isTO?JE ڤ盻X"Ui7N/R dXㄦ:)@ #ƑT%̲r*K6F& Wb&Wv-ƂTq i 4%>&ZDlfP9-Jw})Pj(Ļ~apcj=nI늖hjұ;x4<<SCEx< _ctНa85Zg<EB-,g$aU"EMd'Ergq9n22y4C@spv$88,枌yD1nY̏դ]?`qߵ3杮$05hL#eFA^*AU,tT˜UK B6~FT-J5 qҝ[Ҥ擹zppWp<j$UmY,( : t P002y"2 DLiY\muT$H˗FvOZU 4KA c/\-ԍ۩lZHPjMVkIv+6?M(C_osFӊ̃&=mASWg@e@+Y?tqܘ */xPlJA2m&QZ䤪3%+t;ZSԯ{Rى$V:-̅9 elhVh U25 ̵܎UF܃>|3N],BgjKٷ<2VH2 Ӷ E ƴ)*{-;ǑVA5+*p2* Ը$KB0q{ӕB|rOJs>8przI#MC{N/_!Z۪<oQtWYJ ޠ9Fr$/Cz#z(Jyj6DVqUD~Y)j$ءPڑ- hU1SA(QwcQJG#!P\ ;EGRGS(P8%&Ft w!1AQaq"2B #3Rbr $4%&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz }!1AQa"q2#BR$3br %&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyzC   (((((((((((((((((((((((((((((((((((((((((((((((((((C   %# , #&')*)-0-(0%()(@! ?pj۸+ͨ#J车q!1ZGXulqswG,\Gqj7%TBt*xMm0s~1ŠX\9OCJ1nIi{q2z̞b׫F7>UcoE-s]j6aϡr+([6$]`Ⱂ_By-$%sTs^RFG^>OL֍&BϚyܤPH5l&ݡCE x"lF{W}y*Oqe1;V}֨d砬= 9lMjiںț BŃeNz46OMK2];T7 p*މ"cRN>oYdSE+sI K"#,sq6c9fASEVEcԄ9!bʙ7ՇۦƟd?nҞo"lîk:ӽ]]]zrrxN8,`k(NƚZװP+-hVjlᖮx]Z۶X" ~i.唞a4dBEo:-,Y7c֋G_g$ dqR/)sI{߇9"bĭARz,,τeqsWӣQꞑ:%/uE s-4@@5BLϛV29L٤:ScvhJU6[*咼A$_!Yܜ7$py5qs4qҤuר\ez-*yG\/OyI^c.%+%>/SEG6+xܘXrcJpSgyw9IX!MEhDSLwC|g0įEmv fm"l-YFdU5v唭RudO ڧZC?z-!.=k 79}-;8+T=+AwzKDRȮ '{X"ӂJF>NKSGj\uCCC,tq]36y\i2.vqޱ(a͜VDVkwfܴ3 ]h8Jn-H5a+q|%T1<ޕa޺+ݱ\˖VF+m,kh]>ЀGJCM*W#WJY9nX/y#y*imAE-j:1p剳i'^T a-]R8}S`zgΌ/,Pjnၚ9&GLP'OϚ2Uإ?GU7lg\W4.x3{M[Ajb0RQ;Y0G Gl@Aּ/o~#1yq֦s|9'AGJ1$KT}n33xH y#5*Ψ4P>pFD+,ϖUewcz"-c`\=ƒ͂9a%媱vJ @(+#Pyac#''v Dnd Xk_vc ˎ+8m̮dGnօ}jKEB 1,FGQWL"5f$M%"}s"t׭vPI^^>n#ӘʑVm.I};UTx^W.D&yYߪ%I(CloR55`֢׉P"`da9dZF=u~ulw*ڢ2\[=ءySCPrr++#%(Jصj6r,yb1[$ ?-(@JQw 5V2eVR_7T7tDg*Җhqkez⓻-΅sREcKN(`1Sa4YpGZ%#-T1G0g4"XuΗR!Oq7Keq55,`Z88Y2V EɐɆ'9$nITk$leWV"U]pzfOO޸`:UpzßAOE'ӒrUQ"vkrJcڹ6:*^J8ܧ5qfPٿbRP6ּⲝJ44/Ҽ]n4Z);3U&=K)L0g5zp)U8tsFUsqPo؇?Z{'y ,yWC52 uUNzg?lĎy>Rɗ)q#,e ߽$=bh1HGЊx$*wgei cߟʳ=[ׇcẙ0IkYZ%c9DhH0.9^){epҊōg#:wTɪzI pjbGcďmF>[SS\Xٍ=Hrfh+,dXu梏 j+']7vx#˖il I"n߉dA{i"qڨRI {*r0@UwZ1Z]*2.{cp1r^LQcU.c\u<;M&8`d Eـ>wvzp)04^+Zw[|bۈ,Y:@qD>-KnzV|錍6PElȨzֺIcN. O F8.Wc'.mJR[2#fCt(nS t nvё;W<~a >U 9 t20E, &;r&5YA8滰ԣR]E{3Vn} [R4LS:[+u&aX9مУvpG OC`Za#\ڦFgC>d4GYžhOGbHn)8۹KDf00IgIm~_k3qD#?g^)N-KjJzW0 *HлJB.ENqV@w$F%FsXkᅒo12s]k$'ZZ%DAwOJ^JEx0`*y]J<$at]z{U#2 *o/jh4BJe/}iS?i\Akm$⦬9eczQ+ ޔPIh7^ ap7KZu9n`j=3ǥSZ*svFٳhRjƖ,iim 4rH;mise4:N.%Z0N:@NvI L99NCYnݑSFzRy^ۓaar3jI@I洭";A=DD2 RȒ"GZk3Ur e1jY#1GEm-1Mt {#;Fՙ&W)BSԍPɤ\>]22Aax{}K!/G^[hV`.Ysȩr0\rzՐ0 h'HzӰ u:;+Sk1UӇ7==~s$skǣ}\lž<@ݹ^?*ZԹ(̠uIo+4 t*)AeON*mȤPZB<=j)¤GaM^ic60lYI.MHRGNdsqhjI!M՛5ЌUw24Uuew[4+ir.DPr8f=9}q+a{KWj5T{G406>Zc^Vo6t_?W Tu'#KDԄڪڌ<ͣmsazqs"@yJJS1$rQ17s[Ԛ Igϴc5B{jk}AcS5hjbziԩ3Z_k'sjf%0I1>⹂O/}dDkH|Hq?G7Ŧo+Z1DžZ3oEdNTUm"*7"Rӯd|kjj/Y x$Sbq) k֡$]ZA""ʣW fKж35V}йY,VfZS̅JO{s沜uG„\?zIpFy=k?@fs۬*y{uݧ#P(@ֹv^d#SU+vcLaiGHv@~n:wxV8ndy33&TuEQ'|*HWug9ݗ"FoP 4sUP{$*i 6hfCa iJod eXʐy.b#\Vc{6\c˂ _ QB21sjLTNnAK2ykɰcZTQ1l=ef!Uc#GNDXV {R<7rxU "] GLty2ɢ[!H4'gcRq3M'AT9)lB0 Qi e NQ5W) Vd`k;JT*Fh'@VZV.ܑj# zұfverTqڭ€sTzdM8Cd NQgʮ}8mW?ww 涣k'rlZ] g#]A,Uk 9&C X3!ҥdr֫^:Yj|ҌyJ;wxHXZM]zEhwQg1Pfl\ssZѢm1k1ґ8=* B@*`yUK(nZc>p {mEd^+k͈@5W5@!.٬YiJ3i,HVM!ih"ݏZhj9tC UJ:iATxRFԶsT]Nijio`fE9I6"W8YsH# Tw,Eg&*q*WGCaAiM QIII\AZ6 ֓zgՎ,Y=IxZkrAbXB:V1mBy&ЊouȽs\YַO6tDtM\@ +A[qgVО($>J̖M7[yVǝrDjsm2EfRm J{;u`UQ`݋>/m@\%RT4^B|w ]%*jC12JK{WAIRAxt6@2wI[0Wav9jZZw=LpL'~LnPu:da56xzr%+*1[s\l7JϝUpzҒh{upkvr(90D5{;pEsy_\ ZoLө-nk4djKҥU%Uќ$9'2S%U%UkwQdֲ#9w*k.'d\rhLNMkB^:幯erYN0JDI-(#\C%p LzGX6>8XWdxaJz{-y5 Yr(˝s1Zegt~Ɖ-qZZ;K¸*ISm;a jƎ1\NVFKyƥ̮RmFjݶ1ܚFԽn2y r @" XnLⴧ4a^I##V,:W*_m <ڻjIoiq å;d:n¿Bq]$`\gEizd\3/@*)V[nۿ9yWp7#Ju~bovikI2V64]Zi&HavQ)˙إ(1d2=RHԦMn.19yRF-KT4y` =>d5:`&cMvzsQK v6øsCܓ;y0aiGþFiXht8%RMnq a\ggGHVc75(K23):N:t3@9fLD2z֞sW2j%6b:ԒN&ʱI.uRycC7YHpLjMeFq\tUMˆWlr_wj~$dWrc9qWxHK|wn)^qRXf^D n^ B-E#ۅ4dHEtU"͸6O[Z&u~b+:bY$k)檬#Z+E>#WiYjx i88ZW;rh՗#4հG"b ۮ1i^*JK#zRc㛸D`Y_:Q{dj6-!$2[ŰNk3 v^:YZY ך.i͹,jU"Q͒k3Q] 4ŸsYʚC dkVI2 㚨JҺ)[>9ZBn8ϫ79KVzfDcj{QZ)-HuK6h& .IImSA̓LI&bP0N/GY<[ m#JNwpJ*.@sڦڡsYf *)#qH ޑ-9W} "CFWA;jmN<$Vr4-55ՙ6VwX皭g>zTP@J潼 ^G+ww;⬊ a|++άZGt#3'&^x?:;r-Ouo#YhU[h/TǧBܵ&h8Y*[ɸf Q[MFvMXxUԭIŃ;%2nbTԯ-L@?*. Ûs.<]?*>|Э{.Pԕ.ǟ*wvRlC`ڕ>/_*l|*xW^" 1:˨ZRB)4yNmn"ݚ.%R=G>"¯VD9? A WBo,h[q[?a❙<{}}SVcu9?Va&>sT>hnblSao%Y 移ww3ǻ?4;p7`n튨A5ոR<Tz*pQ[¶+?SpcۃТ;a/BkY"_tYP\&^^h8Y*[ɸf Q[MFvMXxUԭIŃ;%2nbTԯ-L@?*. Ûs.<]?*>|Э{.Pԕ.ǟ*wvRlC`ڕ>/_*l|*xW^" 1:ڋ(^,w$1ȪЕ/#Xڶ:' Q8KuFB$~ꀢkxoAqH(UXI149ՋPZ->{тXk503cՉ; w5Pwe; ɬu_LUW+3^O4lἛs(: VS;*6ee4<@ W4u 5Z] +5tbTѤK%i#geV7AA߼'Q o,,*<{gt")"Bw"v0Uܙ\lpH49MtLj)͠8"^H|~f8QZ>]Aoz$TckJЩƴ ~qU$gKLf "ۓP=,>BaڬH#ҧ{Px ԭs6p~Q֛eqm,Ta$nL3Tjz\ #J ڋ+J{ضU湗ljvӵ/'NUn,G4FʰL߭.rzXkV.[jhzQ-FhȩI"r;+oJLhzSfcKN]͏L+u2U\Xwe}ͤc+.NW7vڴ@`w5ѤDqJZܨG` JGEMhN!`sA;)^-*y$bq4 _秽H(x+J1g=YYv# )xHsQ%;tbs>fQ 9%ИjB m@yCPN(vvV*yf{Ѝu3GJZ;;\y$M]8&dk5m?ZFQ±\cec8q[/B/UBB I2V+v\- xX^2>B& Іc HΝQljEE[J?h ,Ցsc1$S,)َ| ,aR ^Z>|\)Z?r_i$:xYxʄr*M؇ۆX} tW`EШV kN'h N9 rwW^/V6ΟdygdemZ xVUu.xs o-F>>i|,D*Hs*=Be0}֢"3<`SV4V*VvdT.x¦73ǟ`=( `xU0$N@~=?wR%:3ү[M*>27KS5s1]trӃף?٣?c HΝQljEE[J?h ,Ցsc1$S,)َ| ,aR ^Z>|\)Z?r_i$:xYxʄr*M؇ۆX} tW`EШV kN筨iO}ΓIbZ\E-&dhVnѕj sڅRµ qЬq5Skn5 fz}թXf|Ō|S-F&8eMPiz#<%)ydD*p>aMIƴif%D\s4Nѭb2qW5B7 B:;Tk0dpK^3GՓd¬-{Ƒshn7tSjۅ]?+&Hʣԡ>lGBoຸyn"­=͎6Luc(?03QĢ$SosX.?Ү4bxQZ;?vv2Ml`ŸiYt uds :B2ٹWSVlt]bXAes[L5+ ?UWQ{b- bwڝ̻x^~q֨k:f3p1Wsk]\l֐py@?8U/-T7|Qu͠ԒeIK}AإtI< O'xrV4q侅E*[#,zzfb)?i?}ZHW} *jWE[70SK֬!©j'qJq+3Z )g:`INzXoC?M *sɖ#N2\SbAcZ'-+Hˊfd"?8; ?QmXot֝r{3.[FڡlTzŒ[71sZ#µd/m@܋ȼQpiDwVap翴7Hj#]5y$?KTm ?堧_S(}I, yZjQ<Yp:UFRj+C[ 6x:k$AWqOB>ۜ(մyW0NNJδK_mB9v|U-CPh4$wu3GsZ")krBZ5s~nu ΣawOPHOKU`p$W&;=~qY>/oG73OM«O})=,s=}5ޚϖlSNËF6~BZfDK<:x.fjj / , ]}- vkl2"2zd;ZN[p*b<}[ElkՒ(_@oN pi`"kñ~+^h<\b~Q7hk#]-bу~GaQ:PHF~o}Q|+utuiF8\]\y%ݎ5WrUM/dUQG]Uu֫3MnTSyUnbjWbE&VtnYޅT=7=(UE͊++Uuu7hUG Qz]T@ AC6 5oz%Qu:UNKcGR[UsTk+u3TU'c]THewcvQ*:UTVU:}E;@O!26u` @ *(/p,yQ i! {@0@HA@PF D$BH z> @.(Vf] !E0hDd@$rw"L Ew`w('A@"Hh5d=!@h.\IQbn((t*b`m GX b#pm*#ZDP ,dY].8eE&u(Q+͋4}(o*jخ%| Ě+qvi^**<;޿C#Ɉ.6]o1f)Q(\S( P>ܒ5{*̪AP*[/Cς G0$]e(Yb+IM^ @B!Fucծs*.O:U.qFCvVV)$*,].A*gq]{?֣18wݾλ/wyY}omtwxݴE8TgivwuVq_u{Oq;:T@~Sl\טʸ}?ڟ_z_v,fCe_і9K4~M}}{ߩ%].v}=eQsih;\UhT zUՅUQI4wQ]]+Į.UTQWUU WjSǜШW(%nkB_>9u#]UBUU"HԊt4u1щtiՉQ9UXUj5$1OuUUWx 㚙SSxFA ȫ#8є11h1dbTjZɍ7ZM{C{D<Ҷp)g2Uy+;2,RxTd[hˋTqM:np*)L)` GCNVMIlV:Ttdt1Niܸ-=MN~+& VWfhkc UWʚ"Jy9kHTl9qެC1 ։!Qs\DJ;r*bd"vȨ jhP@+  ͍Cw" Mv YGR*7Q敮\`'5iX,@&ǽSf+OɤbsA R j395-!k4bXB| 5(DRF1QqO jqVuL sJpn#3TVh#9oVE*[Q{20d%9 W9k>>SҬ!I'Fx0rTdWUw<,( yP*։r> F$![1B[Ey"5%hY˰ˇf'h0+Uc+8wWQiIWfdW(溢R.EO;63nE\Q=5Z@G.EKqU"ibÌVW.rFj_u*%r,y4U)Xm&h*c08|ÊF!ӊ`U!&)ЭkeL͗} 28dL TISNVV,@RVmQp|Ev^k$rj@9n7qm D@28={q5&s^/^*DVg`HZ 5֧JcFE#W<&HI(⫙(hq)$lTyɭm ^kNp*fsrd ~珽bĝsֳkd&ĊmVdR@5f jװSk:iܷ2g2P\±snŔUFVnW4ɜgU 3{*:yGOxslY\N*@ȩg3 &v}MKpVIkx-,- 0qK$IҴnI1Hwe=jH[zfِ3M1>lpT?q7&M4:N5(@=M#h4k/ 46Hp!Z;eAe1`MF*!\m:s^ӼG5\ڴlA݇c* ԑ!u`F@j: YqS 3Rsu+NP NDTj쉌 F[r\p'5l+)3B *YJi=DxedW}-Q,[n֬ 4 )=k4sq"XQ%aܓr)d_iΞԩW*1`4F95塼U 0+ 3*RhQIń@*QJU#tH)^MXϞscldH$H#D  R5;Z붃TjJ21TJRfsNTKv,(8k2qoGqyCC 7S,L{P ;hȥHI@qY(ѶAXq֬ުH&Gpg$KYPsQ2E[!YKVȚ\ylGG CwJbѹG+`ȮJCa[+/JΚِy4іՈOZ8Ek\]cBl>!P/[FXܵ*¬YohA>UHFdf^99uEJ㣰U9M|R܁+ܐEgn*,6ZW*KV{y&+ֈjk H rge8.JɛJ +9a4 &4 qT%X͑=*&$tacy&I椎lTI\VPJF!j[ۀg7c!U&BSeԊ63[3ʪzTmiC:L*k>sUj;Jf#`(A4PN(s@-D͚ͼ$* U$B'E5f>(Y0@1DN[4y棞:J9CLḿֳӜ>6U)@G5sa۴圮b+)ŹrOR(Mj@Q Űi4L)DX4&6(Z`W%I]ጚc9Ȩ(ʞO/DZTMY'ag`|VP|nQgM )jQvb+` 2Z7t 5"6 KFjE ӶA,ԩ@[Vk+Y PBZFG"cɫq@P>njd: "0jxcsvpV YL孱VȬ [G+3\EX%o{cW&O$gv6'/VL^"'40$Hc4 F8@;2Xk:cJnybHaS FOe`R`R OTUl6J@_lUFM Ɉt$Vbm͘JDTqm֮.HVsV½[֥ Lʉn(W)Hu14 ,a{T5 1W}6ZϹ7)Nk["NJc+9>T #ZYI2dp>*5]PsXz3p*f5,5Eq8g) wgXk( Q8iK+(4޵y4 E Gz#sH: 99N p(>Y6$`[dym^i}b DR$`j#D˞@QO!=Zmm>25"Yƣu±* `(T64(⁌֘;in8' 8Ƒ*#$b)^HcBV[6]4t8c2H&2IY9!k(2l; ڥZ 81@ ĊQRZt╡VMyimzTFZ1A S$KH*Rb$P*E8c"GrJȧތ|ֱ# {x )X轑jc (" ;QHAҔ C֑(2#)qH8 ',lpit ֩68*Zlf8rO L:lV B' d2Xh7j$3sNTÕ@0:VeC["B9)|*BAF1sM3HNvXځ& З2 bǵJF5:0dPaF6"Rj p+HRV'֕R sQ*UZfRcRHdۉuᝄcGnI3+z8$P0nkhtD69 S 4R6FNW]/qm! UzZ5!y4F2*`*F5r5TH 7@pOZ̫ E-bi x54 RCD/2pD֊ X2 ԛPsڧ@ T1qN0P M4r憌2_ZXfL&܀zfdɭX<-Dbp)IzLRM4nCҨhqsP +@)sDxoJ)4cNH팮HjdɩHcv*AnG''+Jevڲ˒F:\+KNy`w5CE"ZӊbS_!J^j)ⴃWc㊷KRZS@&6)PnJy4͑,I' Z(jP4֕!dLA5:5Mab;TG&{BPXrkG]ݍF ^+,ZZSK$B`H:RB"YyhVc0$wSNf'yU湯lۭ=EI$g`j㖌#S89t $bCI֠DG#_AX7"-[)r\qY`O3V0NJ,wJRsS`8 1Fi i:T0åVpD]5(*&['sNz/5vUe`IY,ƽg֠aJ9&ΣMXm=QJl @ 4#a'򲂴4R2Im[v2+J+ŷi6 Ȩ:"1qރTsM1@vcGJc y%R>0)?Jc)G=h8⚍Zܭ$q> ql`ףh͛BH3]DF"$PQ9"ec7ԊS`Hh]ˊλ,qnROKmn^Q^?s3b(ب \uV,7՝犙+ \HB)XsVcCVҨbuӷ [Q\wcC%!Hi9*yT1CM@3Z"od־ѥa5+NJ͖Lu6*;-2"qLww"g5VqI\yc՘唚M9g$-(jךj\F3YAF(!4&`HA).9q*jdKb1LiU:%g")9Wc&3#`sR"F95qpd' VՃ"<ٳr]mU&*3s%c A Dp)eQxXWsU'qF(n;-*QPKlȦY(;ZX=8s(aT q Z(Mdp#Ppx1LԂ^pF)riI,>~*\v5wYrj7";- խJ9_M2S{fY&hLh}H&!F_UƇS Zp~Rj( 堅lc4l4 BhO@ 9&Er*\Pp=*\T ;8Y,̲rjÂx58^!kr ns.[=JzPISό%c+VV\+OPVweOI \tDhsJ)9P:P!`t3ДMĻLarS@ P) )R F߽@۽*[4) _j\gB@ni*a!3TDiM0.9+'a3V+NE]hϭpGN V(H9vE4fN&cMe|Уup, &JPui³M!Lb0AH(U✊L 5BQ;U@ [P5Z5dj!+ĝ;6,[p+W@hL ?tV*LVTBiJ#Z˜֚6Pi/jn9A40)|)JLoQo4Ԙ9 Z@--PM90R4f f0⁔/5TkxBn L4f|DbL8'W/(d%YsV "zr<Զ nSHtTL&V2[ڭ I%NߞE!93P9cUBzWu5bq2hr0ipEa`%SiI@M MH@F[4 *@H;""bK)b]6F=+59V~ERd!0!oWue8dVb (E-Z(!SHeRFpGzZFjod*nA&# sF2%A @zJƝ B]דuW'-֜Ur)4SӠ2nOJ`*2k7"09`Ng6AVp9{E`U#m&H m o@!l+bGCHmH )`u{5:.N{T%AE0 k_5Z_0_)D]yGu#WWW {qfLZ҇.R/Yؒگ+**1b1iq2P4Pr7|C)&i1ޤLi<ͪ3[UV8Xl8f! #4@ `-Q@iTg4FI2ck&fA?iiMjQFU,@>aWLr7$DILU54 )k['b)5:VMX"[LCfoRh)P`:3)Ǧ*X 1*I@ C{U co<9ql*њTըx&FL CzT&Ia:( Fi * 5c<̵J[FgUVbeK -WN**N Zp!jMDcBvbt=* xZ'Ej:,sܘӁP19jrq9I sTezTP:@Si i 0&jRpiE]Vve :ZLpE h8RrG gTLIí4y8kr'iX{PK5S.۱ltLdU ڪ9(bɦYldqīv47@jV3B0*_"ɧ.)qHodENhT%E)&pdخ TQ֞3I:5Z^rjVf5|溩ġRr[XLӱ չ"#G\@gMl" J|VDVR2\c4?5&`1StGP >Ap¢JhaQU8ͯ^54Cd)Dy՛sw )өNK)>+]]д*Wb?Z皻-ZhVhɠfe#UR]0Z5P=[}XGrMYm g$Q5<8B2{։hTGiw 1MPUɧG&XڡdJ(ZE^s&2ڒϩZ4]iӗU=_14z.I&K&VqYa4.h!Ȩha#u`%b@]m}VAS2vȤu7=00ݚ R9 `"jyG& jx:|_[JAU@W4@3ɵp:CFd%(LV @4p)`:A+! hZ1vewmȪ.G mդpEi$*N bS=3S{#*WU7IWj$Z61CzT4N͞LOV )IA)9XR)NRmB2e[I+LYLԕ/q0.%-P{z< tF"l S2֎Lt5W@&ɇ!M7t<)2͟Z0 XԦhvUXdlPёP!xhA* 3wqQaD]H9ljlړK+MahI,֬QYU@D3ɦ\H2z éFQ}ϚIhHNPma 84<ӔsHHx摔G+Ks|y֢hq1]wSТgz 9a$Ze 95(l zHRXTl Pq ktuwDr3A#l15NDu+"IZ~FM C͉FV85XNKaXihNWF5b\Rpk;_sqH=8 $  E?wV39yI'ZAО.SJ#j(RFM`SlD03NI9&) 9niv)]FXd `Y ?Jds"*GS NJk[DMbE1O-hbdbTn` 3U/ 8JJT^ hث"aҔx( SHHlRc$ A2gqFv-WcGhK%MsLvӠa`aɭ+t :ՕI3Q<@ 2$g։\ pW98KWvC1/Lpj3fiȖ\ ֝MgQ #8Dtv4LsJ$Pesx*X37T`)tZf0 0;VrZlȧ :\gV<ؙA+Yjޚ:Wܸ5z 3Q-RmF459 #s~*dc"zCdIZ沣Pσ[Sl xۊ7TLXF@)jdQYzT1K)HuTYHaUTUW8"đ8 oDKg8z j2F(9tn(ȥrC# 4:`qL5;F"j*婳ŕVl$&f[5zD5~1 ` UypE8[Bwfvc *E8Ws# 3`cQFkHRCuPy$Q&V*xVcY5p+]F [تkZsqV&ړV*mT&dfZx5 g$RD(LQBrM9=i#4ւؤ2fvȦHp(B)=ZĘ85.: mH9"c7$EfSF؄c(;5WT = @O4@/sWQ+bbJ\t%)ʘy&2O20OzQݏw :֔j1c5 'T9 ȠVQbJ`6@OJ4Dpv&6(柌 MdR@ 8jWv4W-TshZ%*۔("f㨅)n\1&1C'4pn@IQcKdoݭKQ& 2u@TOjdnqaMƥQ<8$4(#E;8"t*if'8Lq֣3zּ,wokG5 7QMAʚQ$Z]=Stej\*"敍.AMITi Hd J TԑA(%sO1fZ175-&Ozp%2ԴL i Q3)j] 0jEck$SckU14^w; nè8 $P>j}^ry 9=ٯ $aV81=V6); p(*sO ց vSƑzRxHh!FiM;HER$xPbd$\Rcu@ecp+Rek 0-ͧXU:W,:)(dg;2T : Q*Æ)zͱka%Z)+h) rI_, ⊿D;Vh@):5X{RfRdʀSI):SXc4]ɽ_4yZWe*0JnRZF!HעTeaȠS)  P{PZ+֜Sr+:4ZHԮj9PՅ+DC6*"sTPf<E@4*'r;T%84ZDeq IEJ8&J#*eRl͏QPOpI+(rKTfkNCT@ͼ*V4EԊ TIƒޘ9jH1إdaQZbӗ h#59*Tk.EBd T@NHȯS0022Vv&>ĹHQTq\I \'sZ"0+މ,T/Xaj)YH m Ӷ0Ư$s ^v*l#CaQLQR &H8⍤P$9`"^Y ^(R4g*4jգ.bC@1=jF^ Lss+.[O^8SHgּ$B[dPFf .+! SU92[Cћd/Յ楙qRi8kE)qLFxFi("&"Ј5+2)lŕ>shVH ƣԗ4|sPrsR/HE"ӕԘTg3l+C0W2V z sVZ,/Jkyb*NsY-z~nlDLjys!H!$TG=yĄ7zWTv6l $*n4 \VrͳDhUlG4KbSՉ8K, t`ZE IfnMuSa6Y59Q7zKnY65N SLVG/1֕AH+6)I4$P¦R1#H1֥4HHZ66) ݓMb{SFR"9NjsBiEۃѝFMAqxޢ3hT])mTO&hHț&r)79<՝LzaռF W,C# J:ӵR6ϜTh喭[VcE% *E`F*7Er*\Sbx: 5 R*V AMv+ MF皸3VŀZarMsM{تTY'$`S+QKQت쑎Ջ٥5@w yu/q\_"jZ-9U֓zjX32)#*&zhc$pnUZRصuOS1[/SMsP7N[V!rZ`((#1k!WCb;|Sv% HtC7Jv-%(Ϟr+N]K%HCmK5 SwFkcH Fܫ V$l2Y+VQ1ND/Zn$(?( #-R&ŅGZxbؘ"=*l LLk.M5TMP0(<`  j']„"Ve 83Cd㍏8`5?)s]ƍ,aɫm\35I"$LvS n#UfZ; CTc(G"=zԜ.#WJ PN5߀zTW$Mn@bI8kffftGb$^ -5B~2ny^QSdtCRJsCj 䏎`FTԝW40ȟJ씏+VVL-+޵,$\ZS\aɦ2qZ%-HX|GЧdBdTR fخPr0*{{p:֮p!ɨdIڙֈ,Yǽg4e-NYdC2R՛2jiP4{փR(^h.:E8c)VLn5-ֶ X+46*tY7J[Ҳ%*vh"Ԅqr3t !bayL℀P8 4pk@'SO"  J:ePGZ1Kf68cɷYڪM]8B1BϚՎEwds3'˫@e]Ză56"h۷ W="LIa / 5}nYFV0WE)T*vi WvT)fl"xԝЍJ05?. MzqHBTwpٔAt4,V\%g&L@R鰇1Zj?4)JZ,%0aų:,0JoLUsXvm=*L1&zqW9scF2*וIKSHX(i/xF75+6TJI+Nj=jR,alh͒qDA.Uf:c5e=Hhp#N0GZh9ztd8*&s"B]i*u!>VLtg62$8tNkCVl‚8)-#:'5L=tز)n\(n;>kgO[Sua~͹x6֡H'Sf+S6q\qJ)Q| !w8͸='f[rW:x^qWh1V"8H#GJ 0hh̋^F.ThRMXihEj9W\H +ڮs&FMQFM6&FyJ:b R+Jc)(LLjjTTe.N'CхdzM<|IA) lQ14ІMj* P: B8q֓ &s50@RG=ęZ[5w@݈ \+TBp bs17PV('Vt`@XE% Lc B['pja7uO)A^' AҸJR5- SQ5IKؐqPJhDX0Su![B픠Ӊ᪔+ȭ.V\fL|ֈJʶ7Hd94y16 i@iܖ1XܞIL,\d*\h͞5cZBY.sA֚[" U3QK e  j'(0[QRT$ V͑nՒ%;QlZg%_('+B0\TEuLO.[+\-nir=#T-o%nzTJDl=9"HqHސ*i@#QzBI&V"eV=*ș SZ9^AaR2%s1'lQ`R O= UrVAYS:SlDLsSc5 cO H(41TFy⅏5[ EDI,tc@Rc֐UyБ(I. @k"*j1.H5HGdyrԨ lX0hw 3TfJr ԞhCPfPg-AqACwsHIצEJ45`IdT$* Ec-Q&VV)jmT/dcJFMI+Y确r6fз\Jv- VrV̧gĎjrF3Op+o2xh~ASHK -STȑSRbz !XkSFFM4 5FɺǎnQaQu6-.RH’3VAR0W4L ?Zj(ݓRLdW2(8L5U EJVm(B+9kզ(֞- *u"ԎHN6cn!5Rf,*2{G B*(+_8\V5 bH\P+YFe ME 'ҷov)ڳ5L-Ak1Z֧q= ^LRB$97'v!2akĠ$[AiီVRBHe qV-!: .x,NMG(VZH(A8U%\ѨƋoh L,:hϔAs'/R*źq޺$Mkapi[;n =HrH'O OJ(4 ~ &2 Tax/hc Vԑj+ʥ$CE=kgi#]=M90k]@d1=d8HyQL8 1kFZa4) 1EF>wR)hWDPҥ=DA"rCASE @l[)hkH9vqDѤK)[fb,MsM$9%$B ѱԵlϼ`c*+E1<+ЁiM7`&cVr8gO9戚Ka#NMQ˶ksH 8`P3QY&(O Ml:JE3^QB3Hޓb. iP$!cIz;R ,O!l\J%3nqkw;KJRCYXSGC-@s̡HȠt + ,*1sFAVmVdm0!5W$QP3O#\M?9rM=Rb`Ӹ&^nF2NѵD֝*R' DSJNhhJ 1(HV( h~@!K K`i- y*L\{T@ÃRь49" PcpKRi3ɠb8'4`qPyE"E&+ E Zn~ZE") 5}e\㊙[͢yEӨ6 nd8&Z)=DyK 2http://www-medlib.med.utah.edu/WebPath/ORGAN.htmlyK dhttp://www-medlib.med.utah.edu/WebPath/ORGAN.htmlDyK hhttp://cats.med.uvm.edu/cats_teachingmod/pathology/path302/gyn/gynel/cervix/gyncervi.htm#anchor19391320yK http://cats.med.uvm.edu/cats_teachingmod/pathology/path302/gyn/gynel/cervix/gyncervi.htmanchor19391320mDyK >http://www.bioscience.org/atlases/tumpath/freprod/freprod.htmyK |http://www.bioscience.org/atlases/tumpath/freprod/freprod.htm'D@D NormalOJQJ_HkHmH sH tH \@\ Heading 1$$ 0@&a$56@CJKHOJQJ\@\ Heading 2$$ 0@&a$56@KHOJQJ]`@` Heading 3$$ 0@&a$5>*@CJKHOJQJ\Z@Z Heading 4$ 0@&5>*@CJKHOJQJ\b@b Heading 5$ 0Z@&^Z5>*@CJKHOJQJ\DA@D Default Paragraph FontVi@V  Table Normal :V 44 la (k(No List P@P TOC 1, (#$0*$]^`0L@L TOC 2( (#$0*$]^`0L@L TOC 3( (#$p0*$]^p`0L@L TOC 4( (#$@ 0*$]^@ `0L@L TOC 5( (#$0*$]^`0D@D TOC 6  (#$0*$^`0:@: TOC 70*$^`0D@D TOC 8  (#$0*$^`0D@D TOC 9  (#$0*$^`0P @P Index 1( (#$`*$]^``P @P Index 2( (#$0*$]^`0@.@@  TOA Heading*$ (#$."@. CaptionCJ:O: _Equation Caption4@4 Header  !.)@. Page Number@Y@@  Document Map-D OJQJ4 @4 Footer !PB@P Body Text!$ 0a$@CJKHOJQJNP@"N Body Text 2 " 0@CJKHOJQJ6U@16 V,: Hyperlink >*B*phFV@AF b(4FollowedHyperlink >*B* phjSj _ Table Grid7:V%0%@c Table Professionall:V&0j%  &5B*\`Jphff !z!z!z!z!z z!z z z z z zK w&-07c>[G4PdZaf vO  56Y uv}~*567>?zMtuvOMNmn% w { P fTIJKUV]|2!  %&F!$cdV W !!!!!##)$*$$$%%v&w&&&&& '`'m't'~''''L((((***+++`,,,,,,,, /q//&00001?2@2=3t334444N5O5P5Z5^5g5h5m5o5t5u5~5555555555078Y8g8u888888899.::::q;;;;<<F<<<>.>K>b>c>%?+@,@-@L@M@@BAAAB=BwBBBBCFDGDXDDD}EEE*FFFF[G\GII;JSUVyVzVVW:W_W|WWXhXiX}X~XXYY5ZcZdZ[[ [ [6[7[^D_E_H_I__'a(a7aabbccKcccddeeeeeeeeeeef$5$5$x$x$$x$0$0$$$$x$5$x$x$0$0$0$0$x$x$$$x$x$؈$x$x$x$x$x$$x$x$x$x$x$x$x$x$x$x$x$x$x$x$x$x$x$x$x$x$x$ $XM$ $XM$x$x$ $x$x$x$x$x$x$x$ $$x$x$x$x$ $ $x$x$x$x$x$x$x$x$x$؈$؈$؈$`$؈$x$ $x$ $x$x$x$x$PG$x$x$x$x$x$x$x$5$x$@ $x$؈$x$؈$x$`$x$ $x$؈$x$x$x$5$x$0$0$0$$$x$x$x$x$x$x$x$$x$x$$x$x$0$0$x$x$$x$$ $XM$XM$XM$x$x$x$x$x$PG$XM$XM$XM$x$x$XM$XM$x$x[// //[xx xx[xx xx[xx xx$x$x$x$x$x$0$0$0$x$x$0$0$x$PG$x$؈$x$x$x$x$0$0$0$0$0$0$0$x$x$x$x$x$x$x$x$x$hG$x$hG$x$x$x$x$؈$x$0$0$x$x$؈$x$x$x$؈$x$x$x$x$x$x$x$x$x$|$@ $x$x$x$x$x$x$x$x$xx#xx0x4x|x#xx0x4xxx#xx0x4xxx#xx0x4xxx#xx0x4xx$x$ $$$ $x$x$x$ $x$x$x$ $`$x$x$x$x$ $x$x$x$x$x$0$0$0$0$0$0$0$|$x$ $x$ _$0$0$0$x$x$x$x$x$x$ $x$x$x$R"$x$tA$x$x$$x$x$x$x$5$0$؈$x$$x$0$x$x$x$hG$tA$ $x $ $ $ 56Y iuv}~*567>?zMtuvOMNmn% w { P fTIJKUV]|2!  %&F!$cdV W !!!!!##)$*$$$%%v&w&&&&&& '`'m't'~''''L((((***+++`,,,,,,,, /q//&00001?2@2=3t334444N5O5P5Z5^5g5h5m5o5t5u5~5555555555078Y8g8u888888899.::::q;;;;<<F<<<>.>K>b>c>%?+@,@-@L@M@@BAAAB=BwBBBBCFDGDXDDD}EEE*FFFF[G\GII;JSUVyVzVVW:W_W|WWXhXiX}X~XXYY5ZcZdZ[[ [ [6[7[^D_E_H_I__'a(a7aabbccKcccddeeeeeeeeeeeeeeeeeeeeeeeeeeeffff00000505 0 0 0 0 000i00v0v 0v 0v 0v 0v00000>0>0>0>0000000000000000000000000(00  0 0  0 0 (0 0000000(0 0I0000V0V0V0V0V000000000%0%0%0%0%0%!0%!0%0%0%0%0%0%0%0%0%0%0%0%0%0%00!0!0!0!0!0!0!0!0!0!0!0!0!0!00&0&0 0 ' 0 ' 0 '0 '0 '0 '0 '0 '0 '0 '0 '0 '0 '0 '0 '0 '0 '0 ' 0 ' 0 '0 '0 '0 '0 '0 ' 0 ' 0 ' 0 ' 0 '0 '0 '0 '0 '0 '0 ' 0 ' 0 ' 0 '0 '0 ' 0 ' 0 '0 '0 '0 ' 0 ' 0 ' 0 ' 0 ' 0 ' 0 ' 0 ' 0 ' 0 ' 0 ' 0 ' 0 ' 0 ' 0 ' 0 ' 0 '0 '0 '0 '0 ' 0 ' 0 ' 0 '0 '0 ' 0 ' 0 '0 '0 '0 '0 '0 '0 '0 '0 ' 0 ' 0 ' 0 ' 0 ' 0 ' 0 ' 0 '0 '0 ' 0 ' 0 ' 0 '0 '0 '0 '0 '0 '0 '0 '"0 '"0 '"0 '"0 '"0 '"0 ' "0 ' "0 '"0 '"0 '"0 '"0 '"0 '"0 '"0 '"0 '"0 '"0 '"0 '"0 ' "0 ' "0 '"0 '"0 '0 '0 '0 '0 '0 '0 '0 '0 '0 '0 '0 '0 ' 0 ' 0 ' 0 ' 0 ' 0 ' 0 ' 0 ' 0 ' 0 ' 0 ' 0 ' 0 ' 0 ' 0 ' 0 ' 0 ' 0 ' 0 ' 0 ' 0 ' 0 ' 0 ' 0 ' 0 ' 0 ' 0 ' 0 ' 0 ' 0 ' 0 '0 '0 '0 '0 '0 '0 '0 '0 '80 '80 '0mN0mN80 '80 '0+O0+O0+O0+O 0+O 0+O00080000000 0 0 0 0 0 0 00H000 0 0 0 0000080800000000008000000 000 00 0000000000000000000000000 0y0 000X000|X Y iZL[LyLzLLLLLLLf@ 0@0 @ 0 @ 0 @ 0 @ 0 @ 0{00@0  {00@ 0{00@0{00@L0GE{00 @0rXGG0 ((((>Ai 4 N7'@~K3!#%(+./35<?BFDCI}LQT:W<[^7ck"lmnn8;=>?@BCDEGHIJKLNOQRSUV\^_abdfmnprstvx nJ$.4P=g=o===@KFXLT[TyTTTTU]clmn9<AFMPTWXYZ[]`ceghijkloquwn:Nr 6 N P ( ?d2} "@kn_+++UUVVYVwVQccc$dddekeefXXXXXXXXXXXXXXXXX #-46A!!!T8@(  TB  c $DoB S  ?E_fjjt _Hlt126693388 _Hlt126718204 _Hlt159114319 _Hlt126693408 _Hlt126693996 _Hlt159114620 _Hlt126669111 _Hlt126669020 _Hlt126669166 _Hlt95268942 _Hlt126718150 _Hlt126666291 _Hlt126666292 _Hlt126669056 _Hlt126669177 _Hlt126669223 _Hlt126669316 _Hlt126669064 _Hlt126669188kH I K cccccddddteteeef@@@@@@@@@ @ @ @ @ @@@@@@lI J L cccccddddueueeefP,{P{$$%$f$6lt@[4[4^5^5)K)Kf^4^4f5f51K1Kf9*urn:schemas-microsoft-com:office:smarttagsplaceB*urn:schemas-microsoft-com:office:smarttagscountry-region8*urn:schemas-microsoft-com:office:smarttagsCity 4Jp45>KT~*3DJMXcmSW`gN]^f{ 7 > T_`dAK 0:o~ muRZ ="E"H"S"\"h"""*$2$$$%)%3%=%w&&**Q+]+++00P5Y577::>>>>F@J@pAsA|AAAABBFCPCWCbCcClCuCCCCDD:DBDDDFFHHNNRR^SgSTTFTPTTTUUhUoU}UUUUVVVW@WBWXXY$Yp\t\3^9^m_w_____ddeeeeeff4x""xBB2R8RRRVW[[\\cceeeff::::::::4*5tNm @fK]2$`''((++,,3=3P55Y88q;;;<F<<>b>-@M@wBBGDXDJJLLmNNNN4S>S:W|W__eeeeeeeeeeeffeeeffQ x 5[ fJ{MRMu,P*1 A y2cc=ʘwrAXRBzgB[wDn I6F8JV,0L?L >*Y#tcJ_k$_f +jn,'m69Fr ̝Qs, #\w^Y]x(h^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHh ^`OJQJo(h ^`OJQJo(oh pp^p`OJQJo(h @ @ ^@ `OJQJo(h ^`OJQJo(oh ^`OJQJo(h ^`OJQJo(h ^`OJQJo(oh PP^P`OJQJo(hh^h`56CJOJQJo( ^`OJQJo(o pp^p`OJQJo( @ @ ^@ `OJQJo( ^`OJQJo(o ^`OJQJo( ^`OJQJo( ^`OJQJo(o PP^P`OJQJo(^`o()^`.pLp^p`L.@ @ ^@ `.^`.L^`L.^`.^`.PLP^P`L.h^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hH^`o(. ^`hH. pLp^p`LhH. @ @ ^@ `hH. ^`hH. L^`LhH. ^`hH. ^`hH. PLP^P`LhH.h^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHhh^h`56CJOJQJo( ^`OJQJo(o pp^p`OJQJo( @ @ ^@ `OJQJo( ^`OJQJo(o ^`OJQJo( ^`OJQJo( ^`OJQJo(o PP^P`OJQJo(h^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHh   ^ `OJQJo(h ^`OJQJo(oh ^`OJQJo(h | | ^| `OJQJo(h LL^L`OJQJo(oh ^`OJQJo(h ^`OJQJo(h ^`OJQJo(oh ^`OJQJo(h ^`OJQJo(h ^`OJQJo(oh pp^p`OJQJo(h @ @ ^@ `OJQJo(h ^`OJQJo(oh ^`OJQJo(h ^`OJQJo(h ^`OJQJo(oh PP^P`OJQJo(h ^`OJQJo(h ^`OJQJo(oh pp^p`OJQJo(h @ @ ^@ `OJQJo(h ^`OJQJo(oh ^`OJQJo(h ^`OJQJo(h ^`OJQJo(oh PP^P`OJQJo(hh^h`56CJOJQJo( ^`OJQJo(o pp^p`OJQJo( @ @ ^@ `OJQJo( ^`OJQJo(o ^`OJQJo( ^`OJQJo( ^`OJQJo(o PP^P`OJQJo(h^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hH^`o() ^`hH. pLp^p`LhH. @ @ ^@ `hH. ^`hH. L^`LhH. ^`hH. ^`hH. PLP^P`LhH.h^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHh ^`OJQJo(h ^`OJQJo(oh pp^p`OJQJo(h @ @ ^@ `OJQJo(h ^`OJQJo(oh ^`OJQJo(h ^`OJQJo(h ^`OJQJo(oh PP^P`OJQJo(^`o(. ^`hH. pLp^p`LhH. @ @ ^@ `hH. ^`hH. L^`LhH. ^`hH. ^`hH. PLP^P`LhH.^`o(. ^`hH. pLp^p`LhH. @ @ ^@ `hH. ^`hH. L^`LhH. ^`hH. ^`hH. PLP^P`LhH.hh^h`56CJOJQJo( ^`OJQJo(o pp^p`OJQJo( @ @ ^@ `OJQJo( ^`OJQJo(o ^`OJQJo( ^`OJQJo( ^`OJQJo(o PP^P`OJQJo(8JY]x*Y{MzgBL?L5[ 9Fru,Qscc=#\w$_A y2+j I*1cJ_[wDQ ,'mRBwrA                  .                                                              .                          p                 .                                                                       .        ?>@5\% fg;d$j&( 3.%3b(4:45 9V,:$G*8G1{L XS]rcsE  y349? Q?XB7.Hc8 e{[hi}_EP5Z5^5g5h5m5o5t5u5~55555555JLLL.LFLZL[LeLjLoLtLyLzLLLLLLLLLLLLLLLLLLLeeeeeef@hp LaserJet 1012Ne01:winspoolhp LaserJet 1012hp LaserJet 1012<4XSDDMhp LaserJet 1012-ddhp LaserJet 1012<4XSDDMhp LaserJet 1012-ddee`eef`@UnknownGz Times New Roman5Symbol3& z Arial?5 z Courier New5& zaTahoma;Wingdings"9A)jFjF r9/V 3/V 3!)>4dee  3Q)HX(?V,:2 VULVA AND VAGINADr. Carlos T. EscofferyDr. Carlos T. Escofferyh                  Oh+'0 0< \ h t  VULVA AND VAGINADr. Carlos T. EscofferyNormalDr. Carlos T. Escoffery2Microsoft Office Word@z@.http://www.bioscience.org/atlases/tumpath/freprod/freprod.htmr-Yhttp://cats.med.uvm.edu/cats_teachingmod/pathology/path302/gyn/gynel/cervix/gyncervi.htmanchor19391320G]*2http://www-medlib.med.utah.edu/WebPath/ORGAN.html?4'Bhttp://www.gfmer.ch/Books/Cervical_cancer_modules/Images/MI15.jpg24$Bhttp://www.gfmer.ch/Books/Cervical_cancer_modules/Images/MI18.jpg?l!Bhttp://www.gfmer.ch/Books/Cervical_cancer_modules/Images/MII5.jpg4QShttp://www.brooksidepress.org/Products/Military_OBGYN/Textbook/Vulva/SqCaVulva.jpgG Qhttp://www.brooksidepress.org/Products/Military_OBGYN/Textbook/Vulva/vulvaca.jpgIqNhttp://www.brooksidepress.org/Products/Military_OBGYN/Textbook/Vulva/vin3.jpgX :http://www.visualsunlimited.com/browse/vu364/vu36461.html.*<http://www.phac-aspc.gc.ca/slm-maa/slides/hpv/pages/16.htmlb_http://www.brooksidepress.org/Products/OBGYN_101/MyDocuments4/Text/Vulva/HerpesVulvitis640.jpgq Thttp://www.brooksidepress.org/Products/OBGYN_101/MyDocuments4/Text/Vulva/2syphb.jpgJ! Shttp://www.brooksidepress.org/Products/OBGYN_101/MyDocuments4/Text/Vulva/1syph.jpg.Qhttp://www.brooksidepress.org/Products/OBGYN_101/MyDocuments4/Text/Vulva/LGV.jpg+Uhttp://www.brooksidepress.org/Products/OBGYN_101/MyDocuments4/Text/Vulva/LGV1640.jpg0HShttp://www.brooksidepress.org/Products/Military_OBGYN/Textbook/Vulva/Bartholin.htm  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxy{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\^_`abcdfghijklqRoot Entry F`OsData z1TableUWordDocument<SummaryInformation(]DocumentSummaryInformation8eCompObjq  FMicrosoft Office Word Document MSWordDocWord.Document.89q